People: Cumberland Pharmaceuticals Inc (CPIX.O)

Summary

Name	Age	Since	Current Position
A. Kazimi	54	2011	Chairman of the Board, Chief Executive Officer
Rick Greene	48	2011	Chief Financial Officer, Vice President
Martin Cearnal	68	2008	Senior Vice President, Chief Commercial Officer, Director
Leo Pavliv	52	2012	Senior Vice President - Operations, Chief Development Officer
James Herman	57	2011	Vice President - National Accounts, Chief Compliance Officer
Gordon Bernard	61	2010	Director
Robert Edwards	85	1999	Independent Director
Jonathan Griggs	78	2010	Independent Director
Joey Jacobs	59	2011	Independent Director
James Jones	65	2010	Independent Director
Thomas Lawrence	73	1999	Independent Director

» Insider Trading

Biographies

Name	Description
A. Kazimi	Mr. A. J. Kazimi is Chairman of the Board, Chief Executive Officer of Cumberland Pharmaceuticals Inc. He founded the company in 1999. His career includes 25 years in the biopharmaceutical industry. Prior to joining the company, he spent eleven years helping to build Therapeutic Antibodies Inc., an international biopharmaceutical company. As President and Chief Operating Officer, he made key contributions to that company’s growth from its start-up phase through its initial public offering and product launches. Mr. Kazimi oversaw operations in three countries and was personally involved with the company’s product development strategies, approvals, licensing agreements and the raising of over $100 million in equity and debt financings. Prior to that role, Mr. Kazimi worked at Brown-Forman Corporation, rising through a series of management positions and helping to launch several new products. Mr. Kazimi previously served on the board of directors for Aegis Toxicology Sciences Corporation, a federally certified forensic toxicology laboratory. He currently serves as a director of the Nashville Health Care Council, an industry association representing the concentration of healthcare companies in the United States. He also serves as Chairman and Chief Executive Officer of Cumberland Emerging Technologies, Inc (CET). He holds a B.S. from the University of Notre Dame and an M.B.A. from the Vanderbilt University Owen Graduate School of Management.
Rick Greene	Mr. Rick S. Greene is Chief Financial Officer, Vice President of Cumberland Pharmaceuticals Inc., since October 18, 2011. He had previously been serving as the interim Vice President of Finance and Accounting since April 2011. He has more than 20 years of experience in financial management and reporting. From 2007 to 2011, Mr. Greene worked with Crowe Horwath's Tennessee healthcare practice, where as, he developed and led a financial advisory team serving private equity firms, technology, pharmaceutical and other healthcare companies. From 2005 to 2007, Mr. Greene served as Director of Financial Services for LBMC's Healthcare Group. He previously served from 2002 to 2005 as Chief Financial Officer at Surgical Alliance Corporation, a specialty hospital company, and Director of Financial Operations at Phycor, Inc., a publicly held physician management company. Mr. Greene also spent 14 years with national accounting firm Ernst & Young where he served in various roles of increasing responsibility. He holds a B.S. degree from Carson-Newman College.
Martin Cearnal	Mr. Martin E. Cearnal is Senior Vice President, Chief Commercial Officer and Director of Cumberland Pharmaceuticals Inc. In 2008, he joined the management team to head commercial development for Cumberland, currently serving as Senior Vice President and Chief Commercial Officer. He is the former President and Chief Executive Officer of Physicians World, which became the provider of continuing medical education during his tenure from 1985 to 2000. Physicians World was acquired by Thomson Healthcare in 2000, and Mr. Cearnal served as President of Thomson Physicians World from 2000 to 2003 and Executive Vice President-Chief Strategy Officer for Thomson Medical Education from 2003 through 2005. He then became Executive Vice President-Chief Strategy Officer for Jobson Medical Information. Mr. Cearnal has 45 years of experience in the healthcare industry and has been involved with the launches of such noteworthy pharmaceutical products as Lipitor®, Actos®, Intron-A®, Straterra®, Botox® and Humira®. He spent 17 years at Revlon Healthcare in a variety of domestic and international pharmaceutical marketing roles culminating in his position as Vice President, Marketing for International Operations. He serves the industry through several organizations, including the Coalition for Healthcare Communication and the National Task Force on CME Provider/Industry Collaboration. He has a B.S. degree from Southeast Missouri State University.
Leo Pavliv	Mr. Leo Pavliv, R. Ph., is Senior Vice President - Operations and Chief Development Officer of Cumberland Pharmaceuticals Inc. He has served as Vice President, Operations since 2003 was named Senior Vice President in 2009 and Chief Development Officer in 2012. He is responsible for Cumberland’s overall drug development, including manufacturing and quality operations, and has 25 years of experience developing pharmaceutical and biological products. From 1997 to 2003, he worked at Cato Research, a contract research organization, most recently as Vice President of Pharmaceutical Development where he oversaw development of a wide variety of products throughout the development cycle. Prior to 1997, he held various scientific and management positions at biopharmaceutical firms including Parke-Davis from 1984 to 1986, Agouron Pharmaceuticals from 1992 to 1997, ProCyte from 1989 to 1992, and Interferon Sciences from 1986 to 1989. He is a registered pharmacist (R.Ph.) and is regulatory affairs certified. Mr. Pavliv holds a B.S., Pharmacy, and an M.B.A. from Rutgers University.
James Herman	Mr. James L. Herman is Vice President - National Accounts and Chief Compliance Officer of Cumberland Pharmaceuticals Inc. He handles all national accounts sales, including wholesalers and retail chain buying offices, managed care home offices and federal government accounts. He is also charged with overseeing corporate compliance efforts. He has been with the Company since 2003 and has 20 years of pharmaceutical industry experience. From 1998 to 2003, he was with Solvay Pharmaceuticals and served as Director of Managed Care and Director of Trade Affairs and Customer Service. From 1990 to 1998, Mr. Herman was with Schwarz Pharma, where he held national sales leadership positions in National Accounts and Managed Care. He holds a B.S. from Indiana University and an M.B.A. from Cardinal Stritch University.
Gordon Bernard	Dr. Gordon R. Bernard, M.D., is Director of Cumberland Pharmaceuticals Inc. since 2010. Dr. Bernard is the Associate Vice-Chancellor for Research at Vanderbilt University, and also the Melinda Owen Bass Professor of Medicine and former Chief of the Division of Allergy, Pulmonary and Critical Care Medicine at Vanderbilt. In addition, he is Senior Associate Dean for Clinical Sciences and Chairman of Vanderbilt’s Pharmacy and Therapeutics Committee, which is responsible for approving the Vanderbilt Medical Center Formulary of approved drugs and therapeutics. Dr. Bernard has been conducting national and international trials of pharmaceuticals since 1980, and he has been steering committee chair of the National Institutes of Health, Acute Respiratory Distress Syndrome Clinical Trials Network since its inception in 1994. This network is the only federally supported, ongoing system for the conduct of research in the hospital Intensive Care Unit, or ICU. He holds a B.S. from the University of Southwestern Louisiana and an M.D. from Louisiana State University. Dr. Bernard maintains an active practice as an Intensivist in the Medical ICU at Vanderbilt and is therefore in a position to observe, firsthand, the pharmaceutical management issues surrounding the care of a wide variety of the most severely ill patients and identify their unmet medical needs.
Robert Edwards	Dr. Robert G. Edwards is Independent Director of Cumberland Pharmaceuticals Inc. From 1991 to 1999, he was Chairman and Managing Director of the Australasian subsidiary of Therapeutic Antibodies Inc., overseeing operations in Australia, New Zealand and Southeast Asia. Dr. Edwards has also served as Deputy Director of the Institute for Medical & Veterinary Science in South Australia, President of the Royal College of Pathologists of Australasia and as a member of the Australian National Health & Medical Research Council. Dr. Edwards currently serves as the Chairman of the Nominating Committee of the Board of Directors. He also serves as a director for CET. Dr. Edwards holds a Primary Degree from London University, Master of Human Physiology from London University and an M.D. from the University of Adelaide.
Jonathan Griggs	Mr. Jonathan Griggs is an Independent Director of Cumberland Pharmaceuticals Inc. since 2010. His career includes more than 40 years in the pharmaceutical and biotechnology industries that includes international experience. He spent 23 years at Warner Lambert Corporation in positions of increasing responsibility becoming its Vice President of Human Resources. During his tenure with Warner Lambert, he provided leadership for the integration of three pharmaceutical businesses into what became Parke Davis, the consolidation in the industry at that time. From 1992 to present, he has been the CEO of Griggs & Associates, a management and human resources consulting firm assisting startup companies and providing critical assistance in turnaround situations. Mr. Griggs also provided the leadership and strategic management for the formation and establishment of the AACA (Antique Auto Club of America) Museum, a transportation museum where he served as chairman and is currently a director. Mr. Griggs has his B.S. Degree from Penn State and attended the Wharton School of Management at the University of Pennsylvania. He was an advisor to Cumberland as a member of the Company’s Pharmaceutical Advisory Board from the Company’s inception in 1999 until he was appointed to the Board in 2010.
Joey Jacobs	Mr. Joey A. Jacobs is Independent Director of Cumberland Pharmaceuticals Inc. since January 1, 2011. He is a healthcare veteran with more than 35 years of industry experience, Mr. Jacobs is currently the Chairman and Chief Executive Officer of Acadia Healthcare Company Inc., a behavioral health company traded on the Nasdaq Global Market. Mr. Jacobs is the former Chairman, President and Chief Executive Officer of Nashville-based Psychiatric Solutions, Inc. (PSI), which he co-founded in 1997 and grew into a $2 billion behavioral healthcare system before the company’s sale to Universal Health Services in 2010. Prior to founding PSI, Mr. Jacobs spent 21 years at Hospital Corporation of America, or HCA, where he served in various capacities, including President of HCA’s Tennessee Division. Mr. Jacobs’ background at HCA also includes serving as President of HCA’s Central Group, Vice President of the Western Group, Assistant Vice President of the Central Group and Assistant Vice President of the Salt Lake City Division. In addition to serving as the former Chairman of the Nashville Health Care Council, he is also the past director of the Federation of American Hospitals and the National Association of Psychiatric Health Systems. He is currently a board member of the Monroe Carell, Jr. Children’s Hospital at Vanderbilt and Mental Health Management. Mr. Jacobs holds a B.S. degree from Middle Tennessee State University.
James Jones	Mr. James R. Jones is Independent Director of Cumberland Pharmaceuticals Inc. Mr. Jones’ 35 year career in professional accounting at KPMG LLP included the role of Managing Partner at their Nashville, Tennessee office from 1999 to 2006. He served in various capacities during his career at KPMG which also included positions at their offices in Jackson, Mississippi, Washington, DC and Greenville, South Carolina. During his tenure with KPMG, Mr. Jones led a team of more than 100 individuals providing accounting services for an client base. Following retirement in 2006, he has served as an advisor and provided various consulting services to several companies, including acting as liaison between management and the board of directors of a long-term care facility and serving as interim CEO of a charitable organization. He is currently a board director and member of the audit committee of Argent Trust Company of Tennessee. Mr. Jones holds a B.S. from Mississippi College and an M.B.A. from Mississippi State University.
Thomas Lawrence	Mr. Thomas R. Lawrence is Independent Director of Cumberland Pharmaceuticals Inc. Since 2003 he has been Chairman of Aetos Technologies Inc., a corporation formed in 2003 by Auburn University to market technological breakthroughs by its faculty. Since 1998, Mr. Lawrence advises business clients on matters of marketing and corporate governance through his firm Capital Consultants. He previously served as Co-Founder and Managing Partner of Delta Capital Partners, or Delta, in Memphis from 1989 to 1998. The partnership made investments in ten early-stage companies which, by 1998, were valued at more than $30 million. Prior to the formation of Delta, Mr. Lawrence founded several companies in the areas of commercial leasing and venture capital financing. He also worked for most of the 1980s as an Institutional Sales Representative and Commercial Leasing Specialist with the Investment Banking Group of Union Planters Bank in Memphis, where he was responsible for the structure and sale of over $1 billion in securities. He holds a B.A. from Mississippi State University.

Basic Compensation

Name	Fiscal Year Total
A. Kazimi	873,350
Rick Greene	298,160
Martin Cearnal	418,160
Leo Pavliv	562,650
James Herman	305,600
Gordon Bernard	--
Robert Edwards	--
Jonathan Griggs	--
Joey Jacobs	--
James Jones	--
Thomas Lawrence	--

As Of 30 Dec 2012

Options Compensation

Name	Options	Value
A. Kazimi	4,738,490	75,330,000
Rick Greene	0	0
Martin Cearnal	7,400	36,371
Leo Pavliv	3,000	13,185
James Herman	0	0
Gordon Bernard	0	0
Robert Edwards	0	0
Jonathan Griggs	0	0
Joey Jacobs	0	0
James Jones	0	0
Thomas Lawrence	0	0

Insider Trading

Name	Shares Traded	Price
JONES JAMES R	1,000	$4.78
EDWARDS ROBERT G	1,000	$4.78
PAVLIV LEO	10,000	$4.78
KAZIMI A J	50,000	$4.78
BERNARD GORDON R	1,000	$4.78
GRIGGS JONATHAN	1,000	$4.78
JACOBS JOEY A	1,000	$4.78
GREENE RICK SCOTT	6,000	$4.78
CEARNAL MARTIN E	6,000	$4.78
HERMAN JAMES L	5,500	$4.78
LAWRENCE THOMAS R	1,000	$4.78
BERNARD GORDON R	1,000	$4.78
PAVLIV LEO	160,000	$3.50
PAVLIV LEO	132,700	$4.78
LAWRENCE THOMAS R	8,000	$3.50
LAWRENCE THOMAS R	6,222	$4.45
MARSTILLER JEAN W	400	$3.50
JACOBS JOEY A	1,000	$7.72
BERNARD GORDON R	1,000	$7.72
GREER LAWRENCE W	500	$7.72
GREER LAWRENCE W	51,813	$7.72
MARSTILLER JEAN W	3,000	$7.72
CEARNAL MARTIN E	3,000	$7.72
KAZIMI A J	35,000	$7.72
GRIGGS JONATHAN	1,000	$7.72

» Full list on Insider Trading

People: Cumberland Pharmaceuticals Inc (CPIX.O)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: